Nevro Corp. Common Stock (NVRO)
5.7350
+0.0150 (0.26%)
Nevro Corp is a global medical device company that specializes in developing innovative solutions for chronic pain management
The company focuses on providing advanced spinal cord stimulation systems designed to improve the quality of life for patients suffering from various types of neuropathic pain. With a commitment to research and development, Nevro aims to deliver cutting-edge technologies that enhance patient outcomes and address unmet medical needs in the field of pain relief. By pioneering therapies and treatment options, Nevro plays a crucial role in transforming how chronic pain is managed in clinical practice.
Previous Close | 5.720 |
---|---|
Open | 5.730 |
Bid | 5.730 |
Ask | 5.740 |
Day's Range | 5.725 - 5.740 |
52 Week Range | 3.165 - 15.98 |
Volume | 232,941 |
Market Cap | 205.41M |
PE Ratio (TTM) | -3.051 |
EPS (TTM) | -1.9 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,819,524 |
News & Press Releases

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · February 26, 2025

BALA CYNWYD, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · February 26, 2025

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · February 26, 2025

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · February 21, 2025

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · February 10, 2025

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSENVRO) to Globus Medical, Inc. NYSE: GMEDNYSEGMED)
By Kahn Swick & Foti, LLC · Via Business Wire · February 10, 2025

Via Benzinga · November 12, 2024

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · February 10, 2025

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSENVRO) to Globus Medical for $5.85 per share is fair to Nevro shareholders.
By Halper Sadeh LLC · Via Business Wire · February 6, 2025

Ademi & Fruchter LLP is investigating Nevro (NYSENVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.
By Ademi & Fruchter LLP · Via Business Wire · February 6, 2025

AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSEGMED), a leading musculoskeletal solutions company, and Nevro Corp. NYSE: NVRONYSENVRO)
By Globus Medical · Via GlobeNewswire · February 6, 2025

Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Via Benzinga · December 2, 2024

Via Benzinga · November 12, 2024

Nevro stock rises as it gains CE Mark for its HFX iQ SCS system, the first with AI-based personalized pain relief. 2024 revenue outlook raised amid positive earnings.
Via Benzinga · November 12, 2024

Via Benzinga · August 7, 2024

Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!
Via InvestorPlace · August 7, 2024